Microfluidic (MF) devices are the test tubes of the digital age, facilitating the development of next-generation therapeutics and diagnostic breakthroughs.
MF devices are the backbone of organ-on-a-chip and human-on-a-chip platforms, which simulate a true biological environment where scientists can find solutions to the greatest medical issues of the day.
Phase, Inc. has developed a 3D printing platform for microfluidics that will revolutionize the fast-growing $17B microfluidics industry.
Phase’s proprietary LE3D printing technology enables unmatched biomimicry. It employs the gold-standard biocompatible material — which is not currently 3D-printable by competitors — and a user interface that allows non-engineers to design and create microfluidics with unprecedented ease.
Backed by an NIH grant, Phase, Inc. is currently working with the Virginia Tech - Wake Forest School of Biomedical Engineering and Sciences to develop a microfluidic device that will allow researchers to develop new brain cancer treatments.
With a team of seasoned leaders in both 3D printing and biomedical engineering with advanced degrees from MIT and UC Berkeley, Phase is poised to lead the microfluidics industry in unlocking the next wave of medical breakthroughs.
